Navigation Links
Amicus Therapeutics Announces Transition of John F. Crowley from Chairman and Chief Executive Officer to Executive Chairman
Date:4/18/2011

CRANBURY, N.J., April 18, 2011 /PRNewswire/ -- Amicus Therapeutics (Nasdaq: FOLD) today announced that John F. Crowley will transition from Chairman and Chief Executive Officer to Executive Chairman in order to devote more time to interests related to public policy, civic service, and philanthropic endeavors. In his role as Executive Chairman, Mr. Crowley will continue to perform his duties as Chairman of the Board of Directors and will advise the current Amicus management team on corporate strategy and the further advancement of the Company's product development pipeline.

"Amicus is in a strong strategic and financial position today as a result of its Phase 3 program in Fabry Disease, a global partnership with GSK Rare Diseases, an exciting pipeline of additional programs, and a dedicated team of employees," said Mr. Crowley. "The management team at Amicus has driven this success to date and the Company is exceptionally well-positioned to advance its vision as a leader in the development of new therapies for rare diseases. In my new role, I look forward to working with the team toward this goal."

"John is an extraordinary leader for Amicus and a champion for the rare disease community," said Donald J. Hayden, Jr., Lead Independent Director of Amicus. "He has developed an outstanding management team at Amicus and we look forward to continuing to work closely with John during his term as Executive Chairman. On behalf of the Board of Directors, I wish John great success."

Matthew R. Patterson, President and Chief Operating Officer of Amicus, has been appointed Acting Chief Executive Officer in addition to his duties as President, effective immediately. The Amicus Board of Directors intends to shortly initiate a search for a full-time Chief Executive Officer and will include Mr. Patterson as a candidate for the position.

"Matt is a proven leader at Amicus
'/>"/>

SOURCE Amicus Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Amicus Therapeutics Announces FDA Agreement to Commence Phase 2 Study of AT2220 Co-administered with Enzyme Replacement Therapy for Pompe Disease
2. Amicus Therapeutics Initiates Phase 2 Clinical Trial Evaluating Amigal™ Co-administered with Enzyme Replacement Therapy
3. Amicus Therapeutics to Present at the 29th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2011
4. Amicus Therapeutics Awarded $500,000 Grant from The Michael J. Fox Foundation for Development of Next-Generation Pharmacological Chaperone to Treat Parkinsons Disease
5. Amicus Therapeutics Announces Third Quarter 2010 Financial Results
6. GSK and Amicus Therapeutics Enter Exclusive Worldwide Agreement to Develop and Commercialize Amigal™ for Fabry Disease
7. Amicus Therapeutics to Host Conference Call and Webcast to Discuss Exclusive Worldwide Agreement with GSK to Develop and Commercialize Amigal™ for Fabry Disease
8. Amicus Therapeutics to Host Its Second Quarter 2010 Financial Results Conference Call and Webcast on August 5, 2010
9. Amicus CEO Represents BIO on Rare Diseases at U.S. Senate Committee on Health, Education, Labor and Pensions Bipartisan Hearing
10. Alzheimers Drug Discovery Foundation Funds Amicus Therapeutics To Advance Pharmacological Chaperone Technology
11. Fenwal Receives FDA Clearance for Amicus(R) Separator With Wireless Connectivity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... NEW YORK , Oct. 22, 2014 ... and dermatology therapies. PV-10, its novel investigational drug for ... the potential for systemic side effects. Its oncology focus ... liver. Provectus has completed phase 2 trials of PV-10 ... as a topical treatment for atopic dermatitis and psoriasis. ...
(Date:10/20/2014)... MOUNTAIN VIEW, Calif. , Oct. 20, 2014 /PRNewswire/ ... field of interventional pulmonology, today announced completion of enrollment ... schedule.  The RENEW Clinical Study is the FDA-approved IDE ... treatment for severe emphysema. It was anticipated ... US in February 2013, would take until the end ...
(Date:10/20/2014)... 2014 Valeritas, Inc., a leader in simple, ... Type 2 diabetes, announced today that it has received ... award was presented October 16 th at Cardinal,s ... . The Cardinal Health Supply ... of metrics specifically targeted at the importance of developing ...
Breaking Medicine Technology:Provectus Biopharmaceuticals Looks at the Asian Markets: Analyst Coverage by Small Cap Traders 2PneumRx Completes RENEW Pivotal Trial Enrollment 2PneumRx Completes RENEW Pivotal Trial Enrollment 3Valeritas Receives 2014 Cardinal Health Supply Chain Excellence Award 2Valeritas Receives 2014 Cardinal Health Supply Chain Excellence Award 3
... Aug. 1, 2011 Biodel Inc. (Nasdaq: BIOD ... results on August 4, 2011.  Following the release of the ... call to discuss the results and provide an update on ... fiscal year 2011 results will be distributed4:15 pm EDT: , ...
... 2011 Reportlinker.com announces that a new ... catalogue: Insulin- Global ... This package contains 63 insulin market analyses ... Czech Republic,Denmark, Estonia, Finland, France, Germany, Greece, ...
Cached Medicine Technology:Insulin- Global 2
(Date:10/22/2014)... October 22, 2014 The ... which is dedicated to distribute health information technology ... delivery worldwide announced the development of six key ... expect when receiving healthcare. These are an expansion ... care: “providing care that is respectful of and ...
(Date:10/22/2014)... Best Cheap Hosting USA is among the most distinguished ... announced that iPower ( http://www.best-cheap-hosting-usa.com/go/iPower/ ) is the best ... world. , “iPower is one of the most reliable ... kinds of useful products for new and old clients. ... service and a number of features which will appeal ...
(Date:10/22/2014)... October 22, 2014 Lintelus, Inc., an ... Vice President of Sales, will be speaking on the ... Technology Expo on October 28, at the Holiday Inn ... a booth as well as a Tech Demo at ... can create a more engaging event experience. , The ...
(Date:10/22/2014)... HealthDay Reporter , TUESDAY, Oct. ... fertilization (IVF) are only about half as likely as white ... new research indicates, and the racial disparity persists even when ... percent of white patients became pregnant after IVF, compared to ... 4,000 IVF cycles over two years to tease out the ...
(Date:10/22/2014)... Measures taken by Firestone officials at the company,s ... the spread of the disease there and could prove ... Co. provides health services to about 80,000 employees, retirees, ... Between Aug. 1 and Sept. 23, there were ... people. That incidence rate of 0.09 percent was much ...
Breaking Medicine News(10 mins):Health News:The Sullivan Institute for Healthcare Innovation Announces Release of Guiding Principles for Patient Experience-Centered Care 2Health News:Best Cheap Hosting USA Has Recently Announced The Best Cheap Web Hosting Companies In 2014 2Health News:Jay Cormier, Sr. Vice President of Sales for Lintelus, Speaks about Event Technology Integration at Meetings Technology Expo in NYC 2Health News:Black Women Fare Worse With Fertility Treatments, Study Says 2Health News:Black Women Fare Worse With Fertility Treatments, Study Says 3Health News:Tire Company Sets Standard for Ebola Care in Liberia: CDC 2
... country's greenest and cleanest city was not enough, Chandigarh is all ... become the first smoke-free city in the country. ... free by July 1. ,The joint capital of Punjab ... and buildings to ensure that smoking is restricted and the general ...
... a million less AIDS patients than has been widely believed, ... were reported here. ,The survey that was ... out under international supervision shows that India probably no longer ... the New York Times said Friday. ,An official ...
... epilepsy in developing countries are being denied an effective ... according to an editorial in this weeks BMJ. ... in developing countries to ensure that effective treatment is ... people with epilepsy who live in developing countries, around ...
... (hESC), those very young cells that are a biological blank ... to the workings of a wide variety of organs and ... slow to be realized because of the ongoing ethical debate ... its a politically charged issue in the U.S. because it ...
... of tumors and the response of tumors to radiation ... in turn limits oxygen delivery to the tumor, causing ... shown to trigger tumor resistance to radiation via the ... known as HIF-1regulated cytokines. In a study appearing online ...
... community hospita,l in Detroit with 285 beds, specializing in general ... failure, diabetes and obstetrics. ,Detroit is the largest ... a prosperous region. ,But Riverview is all ... week said it was losing too much money and already ...
Cached Medicine News:Health News:Chandigarh to Become India's First Smoke-free City 2Health News:India Has a Million Less AIDS Cases Than Believed: Study 2Health News:Dartmouth Professor Makes Case for Ethically Universal Stem Cell Lines 2Health News:Hospitals in Older Cities Close Down, Blacks Worst Affected 2Health News:Hospitals in Older Cities Close Down, Blacks Worst Affected 3
... As the leader in liquid handling, ... Finnpipette Novus, a pipette that combines simplicity, ... ergonomic design. Built on the results of ... the new Finnpipette Novus gives you the ...
... The StaRRsed-III is a system ... human blood samples. This rate may ... patients therapy. The sedimentation rate is ... hence is typically used in high-volume ...
... complete range of automatic systems for performing ... mL of blood. With the introduction of ... clinical diagnostic market a truly revolutionary testing ... limitation associated with the traditional ESR techique.,By ...
... The NEW VACUETTE erythrocyte sedimentation ... can help. The new generation unites ... analysers with whole range of additional ... of the erythrocyte sedimentation rate. Cost ...
Medicine Products: